Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Second-line Gemcitabine Plus Carboplatin After Progression on Enfortumab Vedotin With Pembrolizumab in Advanced or Metastatic Urothelial Carcinoma

NCT07043972 is registered in ClinicalTrials.gov with Fox Chase Cancer Center as lead sponsor.

NCT NCT07043972
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07043972 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Second-line Gemcitabine Plus Carboplatin After Progression on Enfortumab Vedotin With Pembrolizumab in Advanced or Metastatic Urothelial Carcinoma
Lead sponsor
Fox Chase Cancer Center
Phase
Phase 2
Overall status
Recruiting
Start date
July 9, 2025
Completion date
January 1, 2031
Enrollment
55 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

urothelial carcinoma